https://finviz.com/news/337838/can-fite-expands-namodenoson-anti-obesity-franchise-with-israeli-patent-allowance
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Stock screener for investors and traders, financial visualizations.
anti obesityfiteexpandsnamodenoson
https://www.biospace.com/can-fite-breakthrough-findings-demonstrate-namodenoson-anti-cancer-and-protective-effect-mechanism-in-the-liver
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism...
Jun 25, 2024 - Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases,...
https://www.biospace.com/press-releases/can-fite-anti-obesity-drug-namodenoson-received-patent-allowance-in-australia
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - BioSpace
anti obesity drug
https://www.biospace.com/press-releases/disappearance-of-decompensated-liver-cirrhosis-episodes-after-treatment-with-can-fites-namodenoson
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson...